Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial
Titel:
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial
Auteur:
Haddad, Robert Guigay, Joel Keilholz, Ulrich Clement, Paul M. Fayette, Jérôme de Souza Viana, Luciano Rolland, Frédéric Cupissol, Didier Geoffrois, Lionnel Kornek, Gabriela Licitra, Lisa Melichar, Bohuslav Ribaldo Nicolau, Ulisses Rauch, Daniel Zanetta-Devauges, Sylvie Cohen, Ezra E.W. Machiels, Jean-Pascal Tahara, Makoto Vermorken, Jan Geng, Yuan Zografos, Eleftherios Gauler, Thomas